Skip to main content
Premium Trial:

Request an Annual Quote

BG Medicine Regains Nasdaq Compliance

NEW YORK (GenomeWeb News) – BG Medicine said in a filing with the US Securities and Exchange Commission today that it has regained compliance with Nasdaq listing requirements.

BG disclosed a couple of weeks ago that the Listing Qualifications Department of the Nasdaq Stock Market had informed the firm that the market value of its listed securities had closed below the minimum $50 million required for continued listing for the 30 days leading up to Dec. 10. The company was given until June 10, 2013, to regain compliance with the rule.

Nasdaq told the firm on Dec. 27 that it had regained compliance because for the consecutive business days ending Dec. 24 the market value of its listed securities was $50 million or greater.

Waltham, Mass.-based BG Medicine makes the CardioScore and Galectin-3 heart failure tests.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.